Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 12, 2010

View Archived Issues

Novel M. tuberculosis methionine aminopeptidase inhibitors identified

Variations in fentanyl sensitivity correlated with OPRM1 gene polymorphisms

Gene recurrence score may be useful for prognosis in node-positive breast cancer

Javelin reports phase III trial data for Ereska

Nymox provides update on pivotal phase III NX-1207 trials for BPH

Phase II study evaluates droxidopa in combination with carbidopa in adult ADHD

StemCells' HuCNS-SC human neural stem cells used in myelination disorder trial

FDA accepts Alexza's AZ-004 NDA for filing

Data Monitoring Committee recommends continuation of phase III StemEx trial

Correlation between higher blood lead levels and adverse mental health outcomes

Oral cladribine reduces rate of multiple sclerosis relapse in phase III trial

LEK Pharmaceuticals describes novel broad spectrum antibacterial agents

Amura Therapeutics discovers novel CAC1 cysteine protease inhibitors

Aegera presents novel IAP inhibitors

Otsuka Pharmaceutical describes novel monoamine reuptake inhibitors

Ligon Discovery and Lycera collaborate to develop drugs for immune disorders

Data Monitoring Committee recommends continuation of phase III ThermoDox trial

QRxPharma initiates second pivotal phase III MoxDuoIR dual-opioid trial

Antisense provides update on ATL-1101

Astellas reports third quarter 2009 results

Lundbeck claims the identification of novel PDE10 inhibitors

FDA grants approval to Daiichi's hypertension treatment Benicar in pediatric patients

Living Cell Technologies receives government grant for Diabecell

3SBio and Ascentage enter into strategic alliance for targeted cancer therapeutics

Shenogen and Chemizon sign agreement for ERalpha receptor modulators

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.